{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:23:44Z","timestamp":1795119824442,"version":"4.10.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01163-w","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:06:16Z","timestamp":1778576776000},"page":"1064-1079","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-4347","authenticated-orcid":false,"given":"Elizabeth A. R.","family":"Garfinkle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5309-8249","authenticated-orcid":false,"given":"Renzo","family":"Perales-Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Gimple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6483-9153","authenticated-orcid":false,"given":"Kaleigh F.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar H.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Peter","family":"Goedegebuure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gue Su","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasreet","family":"Hundal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-0192","authenticated-orcid":false,"given":"Jaye B.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia A.","family":"Paxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srestha","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Cooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Perales-Puchalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Stavroulaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rochestie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian L.","family":"Campian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan G.","family":"Chheda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Chicoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T.","family":"Willie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Zipfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0843-4271","authenticated-orcid":false,"given":"Obi L.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6388-446X","authenticated-orcid":false,"given":"Malachi","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0465-3071","authenticated-orcid":false,"given":"William E.","family":"Gillanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1054-0476","authenticated-orcid":false,"given":"Katherine E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5892-1553","authenticated-orcid":false,"given":"Elaine R.","family":"Mardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6920-1167","authenticated-orcid":false,"given":"Niranjan Y.","family":"Sardesai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1094-1528","authenticated-orcid":false,"given":"Tanner M.","family":"Johanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02267-0","volume":"24","author":"A Pouyan","year":"2025","unstructured":"Pouyan, A. et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol. Cancer 24, 58 (2025).","journal-title":"Mol. Cancer"},{"key":"1163_CR3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997\u20131003 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro, A. et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro. Oncol. 25, 123\u2013134 (2023).","journal-title":"Neuro. Oncol."},{"key":"1163_CR5","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro. Oncol. 24, 1935\u20131949 (2022).","journal-title":"Neuro. Oncol."},{"key":"1163_CR6","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the Checkmate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003\u20131010 (2020).","journal-title":"JAMA Oncol."},{"key":"1163_CR7","first-page":"360","volume":"38","author":"RD Read","year":"2024","unstructured":"Read, R. D. et al. Glioblastoma microenvironment\u2014from biology to therapy. Genes Dev. 38, 360\u2013379 (2024).","journal-title":"Genes Dev."},{"key":"1163_CR8","first-page":"vdad009","volume":"5","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Tumor microenvironment in glioblastoma: current and emerging concepts. Neurooncol. Adv. 5, vdad009 (2023).","journal-title":"Neurooncol. Adv."},{"key":"1163_CR9","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","volume":"24","author":"P Chongsathidkiet","year":"2018","unstructured":"Chongsathidkiet, P. et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 24, 1459\u20131468 (2018).","journal-title":"Nat. Med."},{"key":"1163_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"1163_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240\u2013245 (2019).","journal-title":"Nature"},{"key":"1163_CR12","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1158\/1078-0432.CCR-23-3077","volume":"30","author":"TM Johanns","year":"2024","unstructured":"Johanns, T. M. et al. Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma. Clin. Cancer Res. 30, 2729\u20132742 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1163_CR13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373\u20131385 (2017).","journal-title":"Lancet Oncol."},{"key":"1163_CR14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.22.00996","volume":"41","author":"MS Ahluwalia","year":"2023","unstructured":"Ahluwalia, M. S. et al. Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 41, 1453\u20131465 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1163_CR15","doi-asserted-by":"publisher","first-page":"ii237","DOI":"10.1093\/neuonc\/noaa215.988","volume":"22","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Ltbk-01. Ino-5401 and Ino-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (Regn2810) in newly diagnosed glioblastoma. Neuro. Oncol. 22, ii237 (2020).","journal-title":"Neuro. Oncol."},{"key":"1163_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau, L. M. et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 9, 112\u2013121 (2023).","journal-title":"JAMA Oncol."},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","volume":"187","author":"HR Mendez-Gomez","year":"2024","unstructured":"Mendez-Gomez, H. R. et al. RNA aggregates harness the danger response for potent cancer immunotherapy. Cell 187, 2521\u20132535.e21 (2024).","journal-title":"Cell"},{"key":"1163_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2159-8290.CD-21-0291","volume":"12","author":"MO Schaettler","year":"2022","unstructured":"Schaettler, M. O. et al. Characterization of the genomic and immunologic diversity of malignant brain tumors through multisector analysis. Cancer Discov. 12, 154\u2013171 (2022).","journal-title":"Cancer Discov."},{"key":"1163_CR19","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat. Med. 30, 1044\u20131053 (2024).","journal-title":"Nat. Med."},{"key":"1163_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1163_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0264-5","volume":"8","author":"J Hundal","year":"2016","unstructured":"Hundal, J. et al. pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 8, 11 (2016).","journal-title":"Genome Med."},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"200835","DOI":"10.1016\/j.omton.2024.200835","volume":"32","author":"JF de Graaf","year":"2024","unstructured":"de Graaf, J. F. et al. Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer. Mol. Ther. Oncol. 32, 200835 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.omto.2021.04.005","volume":"21","author":"PS Bhojnagarwala","year":"2021","unstructured":"Bhojnagarwala, P. S. et al. A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation. Mol. Ther. Oncolytics 21, 278\u2013287 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1163_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11060-025-04952-y","volume":"172","author":"J Pham","year":"2025","unstructured":"Pham, J. et al. Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: insights from the U.S. National Cancer Database. J. Neurooncol. 172, 655\u2013665 (2025).","journal-title":"J. Neurooncol."},{"key":"1163_CR25","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41591-025-03928-9","volume":"31","author":"W Wick","year":"2025","unstructured":"Wick, W. et al. Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1\/2a N2M2 umbrella trial. Nat. Med. 31, 3534\u20133541 (2025).","journal-title":"Nat. Med."},{"key":"1163_CR26","doi-asserted-by":"publisher","first-page":"640725","DOI":"10.3389\/fimmu.2021.640725","volume":"12","author":"WD Chronister","year":"2021","unstructured":"Chronister, W. D. et al. TCRMatch: predicting T-cell receptor specificity based on sequence similarity to previously characterized receptors. Front. Immunol. 12, 640725 (2021).","journal-title":"Front. Immunol."},{"key":"1163_CR27","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-23-0913","volume":"14","author":"AZ Wang","year":"2024","unstructured":"Wang, A. Z. et al. Glioblastoma-infiltrating CD8+ T cells are predominantly a clonally expanded GZMK+ effector population. Cancer Discov. 14, 1106\u20131131 (2024).","journal-title":"Cancer Discov."},{"key":"1163_CR28","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1093\/neuonc\/noaf113","volume":"27","author":"C Ruiz-Moreno","year":"2025","unstructured":"Ruiz-Moreno, C. et al. Charting the single-cell and spatial landscape of IDH-wild-type glioblastoma with GBmap. Neuro. Oncol. 27, 2281\u20132295 (2025).","journal-title":"Neuro. Oncol."},{"key":"1163_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol. Cancer 22, 194 (2023).","journal-title":"Mol. Cancer"},{"key":"1163_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR31","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"1163_CR32","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306\u20132316 (2017).","journal-title":"JAMA"},{"key":"1163_CR33","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp, R. et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314, 2535\u20132543 (2015).","journal-title":"JAMA"},{"key":"1163_CR34","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1163_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0577-x","volume":"16","author":"BJ Kelly","year":"2015","unstructured":"Kelly, B. J. et al. Churchill: an ultra-fast, deterministic, highly scalable and balanced parallelization strategy for the discovery of human genetic variation in clinical and population-scale genomics. Genome Biol. 16, 6 (2015).","journal-title":"Genome Biol."},{"key":"1163_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0666-2","volume":"11","author":"MM Richters","year":"2019","unstructured":"Richters, M. M. et al. Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 11, 56 (2019).","journal-title":"Genome Med."},{"key":"1163_CR37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/2326-6066.CIR-18-0283","volume":"7","author":"EK Duperret","year":"2019","unstructured":"Duperret, E. K. et al. A synthetic DNA, multi-neoantigen vaccine drives predominately MHC class I CD8+ T-cell responses, impacting tumor challenge. Cancer Immunol. Res. 7, 174\u2013182 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1163_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00262-007-0380-6","volume":"57","author":"S Janetzki","year":"2008","unstructured":"Janetzki, S. et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC\/SVI). Cancer Immunol. Immunother. 57, 303\u2013315 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"1163_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1163_CR40","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"1163_CR41","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"},{"key":"1163_CR42","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"}],"updated-by":[{"DOI":"10.1038\/s43018-026-01243-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01163-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01163-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01163-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:35:53Z","timestamp":1788327353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01163-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01163-w","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s43018-026-01243-x","URL":"https:\/\/doi.org\/10.1038\/s43018-026-01243-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.P.L., J.Y., N.C., A.P.P., S.R., J.P. and N.Y.S are either current or previous full-time employees of Geneos Therapeutics. B.J. has a consultant role for Geneos Therapeutics. O.L.G and M.G. have consultant roles for the Jaime Leandro Foundation for Therapeutic Cancer Vaccines and Pathfinder Oncology. W.E.G has a consultant role for Jamie Leandro Foundation. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}